Average cost of multi drug-resistant tuberculosis treatment in Guinea-Bissau
Guinea-Bissau: Average cost of multi drug-resistant tuberculosis treatment was 1,120 constant 2022 US$ in 2024. ◆ Volatile
Latest (2024)
1,120 constant 2022 US$
Change on year
up 34.8%
World rank
43rd
of 92 countries
All-time high
4,129 constant 2022 US$
in 2017
All-time low
295 constant 2022 US$
in 2021
Years of data
8
2017–2024
Average cost of multi drug-resistant tuberculosis treatment in Guinea-Bissau, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
The most recent figure for average cost of multi drug-resistant tuberculosis treatment in Guinea-Bissau is 1,120 constant 2022 US$, measured in 2024.
Compared with earlier readings it is up 34.8% on the previous year and down 72.9% over ten years.
Guinea-Bissau ranks 43rd of 92 countries on this measure, in the middle of the range.
Average cost of multi drug-resistant tuberculosis treatment in Guinea-Bissau, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 4,129 constant 2022 US$ | — |
| 2018 | 1,081 constant 2022 US$ | -73.8% |
| 2019 | 2,234 constant 2022 US$ | +106.7% |
| 2020 | 1,659 constant 2022 US$ | -25.7% |
| 2021 | 295 constant 2022 US$ | -82.2% |
| 2022 | 1,321 constant 2022 US$ | +347.8% |
| 2023 | 831 constant 2022 US$ | -37.1% |
| 2024 | 1,120 constant 2022 US$ | +34.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 2,481 constant 2022 US$ | 1,081 constant 2022 US$ | 4,129 constant 2022 US$ | 3 |
| 2020s | 1,045 constant 2022 US$ | 295 constant 2022 US$ | 1,659 constant 2022 US$ | 5 |
Countries ranked near Guinea-Bissau
More health data for Guinea-Bissau
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7721 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,070 deaths per 1,000 people (2090)
- Number of infants who die before age 1 941 deaths (2100)
- Population ages 50-54, male, annual growth rate 5.68 % change on previous year (2025)
- Population ages 50-54, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 50-54, male, per capita 0.0156 units per person (2025)
- Population ages 55-59, female, annual growth rate 4.67 % change on previous year (2025)
- Population ages 55-59, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 55-59, female, per capita 0.0128 units per person (2025)
Frequently asked questions
- What is average cost of multi drug-resistant tuberculosis treatment in Guinea-Bissau?
- Average cost of multi drug-resistant tuberculosis treatment in Guinea-Bissau was 1,120 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of multi drug-resistant tuberculosis treatment recorded in Guinea-Bissau?
- The highest recorded value was 4,129 constant 2022 US$ in 2017.
- What is the lowest average cost of multi drug-resistant tuberculosis treatment recorded in Guinea-Bissau?
- The lowest recorded value was 295 constant 2022 US$ in 2021.
- How does Guinea-Bissau rank for average cost of multi drug-resistant tuberculosis treatment?
- Guinea-Bissau ranks 43rd out of 92 countries with data for 2024.
- Is average cost of multi drug-resistant tuberculosis treatment rising or falling in Guinea-Bissau?
- Over the last ten years it is down 72.9%. The long-run trend across the full record is volatile.
- Where does this Guinea-Bissau data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of multi drug-resistant tuberculosis treatment. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.